Study Reveals Persistent Tissue Changes in Ulcerative Colitis Despite Clinical Healing
Researchers analyzing tissue samples from 89 ulcerative colitis patients found that mucosal healing—the standard treatment goal—does not represent complete tissue recovery, with persistent abnormal changes in supporting cells remaining even during clinical remission. The study used advanced imaging and genetic analysis to identify three types of stromal cell changes that persist after healing appears complete. These findings suggest that current treatment endpoints may be insufficient and that identifying these cellular signatures could help predict which patients will relapse or fail to respond to therapy.
A comprehensive tissue analysis of 89 ulcerative colitis patients reveals that mucosal healing, the primary therapeutic endpoint in UC treatment, represents an incomplete recovery state marked by persistent abnormal remodeling of stromal cells—the tissue's supporting infrastructure. Using single-cell and bulk transcriptomics, spatial imaging, and multiplexed analysis, researchers identified three key changes that persist despite clinical remission: emergence of inflammatory fibroblasts, loss of protective niche-supporting fibroblasts, and expansion of pericytes with altered matrix-remodeling features. Spatial analyses confirmed that tissue organization remains disrupted even when patients appear clinically well. Across independent patient cohorts, the presence of inflammatory fibroblast and pericyte signatures at baseline robustly predicted which patients would not respond to anti-TNF therapy, a common UC treatment. These findings suggest that the biological state of apparent healing masks ongoing tissue vulnerability and identify stromal cell signatures as potential biomarkers for predicting relapse risk and treatment response.
What's missing
The study does not specify the clinical follow-up duration or relapse rates in the cohorts studied, limiting assessment of how strongly these stromal signatures correlate with actual long-term patient outcomes. The mechanisms by which these stromal changes drive relapse vulnerability remain to be elucidated. The generalizability of findings to UC patients of different demographics or disease severity is not discussed.
What different sources said
- bioRxivCenter
Persistent stromal reprogramming defines incomplete mucosal healing and predicts therapeutic response in ulcerative colitis
Related
Study reveals how replication protein A prevents unregulated DNA synthesis and maintains genome stability
Researchers using Xenopus egg extracts found that replication protein A (RPA) prevents spontaneous DNA priming on single-stranded DNA and blocks inappropriate recruitment of recombination factors. RPA is a critical DNA-binding protein that becomes depleted when cells produce excess single-stranded DNA, potentially leading to replication fork breakage. The findings clarify RPA's protective role in maintaining genome stability and suggest mechanisms by which RPA depletion could trigger genomic instability.
Study reveals mammalian RNA localization elements are large, complex, and multipartite structures
Researchers systematically analyzed tens of thousands of mutant RNA localization elements and found that functional elements controlling subcellular RNA positioning are approximately 200 nucleotides in size and contain multiple critical subsequences. The study used high-throughput mutagenesis in neuronal cells and verified findings with single-molecule microscopy in primary rat neurons. These findings advance understanding of how cells control RNA distribution, which is fundamental to cellular function and may have implications for developmental biology and disease mechanisms.
Leritrelvir Shows Enhanced Activity Against Drug-Resistant SARS-CoV-2 Variants, Study Finds
A new study demonstrates that leritrelvir, an antiviral drug approved in China, maintains stronger inhibitory activity against drug-resistant variants of the SARS-CoV-2 main protease compared to nirmatrelvir (used in Paxlovid). The research used biochemical, structural, and cellular analyses to show that leritrelvir binding restores the dimerization of protease mutants that have developed resistance to current treatments. The findings suggest leritrelvir could be a more effective treatment option as the virus continues to evolve resistance to existing antivirals.